Antengene Corporation Ltd
HKEX:6996
Antengene Corporation Ltd
Common Stock
Antengene Corporation Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antengene Corporation Ltd
HKEX:6996
|
Common Stock
¥454k
|
CAGR 3-Years
1%
|
CAGR 5-Years
45%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Common Stock
¥52k
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Common Stock
¥603.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
14%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Common Stock
¥6.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
8%
|
CAGR 10-Years
16%
|
|
|
C
|
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
|
Common Stock
¥1.4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Common Stock
¥401m
|
CAGR 3-Years
4%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
Antengene Corporation Ltd
Glance View
Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.
See Also
What is Antengene Corporation Ltd's Common Stock?
Common Stock
454k
CNY
Based on the financial report for Dec 31, 2024, Antengene Corporation Ltd's Common Stock amounts to 454k CNY.
What is Antengene Corporation Ltd's Common Stock growth rate?
Common Stock CAGR 5Y
45%
Over the last year, the Common Stock growth was 1%. The average annual Common Stock growth rates for Antengene Corporation Ltd have been 1% over the past three years , 45% over the past five years .
You don't have any saved screeners yet